Drug treatment strategies for insomnia in patients with post-traumatic stress disorder

References

• Ohayon MM, Shapiro CM. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry. 2000;41(6):469–478.
   PubMed Web of Science ®Google Scholar
• McLay RN, Klam WP, Volkert SL. Insomnia is the most commonly reported symptom and predicts other symptoms of post-traumatic stress disorder in U.S. service members returning from military deployments. Mil Med. 2010;175(10):759–762.
   PubMed Web of Science ®Google Scholar
• Seelig AD, Jacobson IG, Smith B, et al. Sleep patterns before, during, and after deployment to Iraq and Afghanistan. Sleep. 2010;33(12):1615–1622.
   PubMed Web of Science ®Google Scholar
• Seelig AD, Jacobson IG, Donoho CJ, et al. Sleep and health resilience metrics in a large military cohort. Sleep. 2016;39(5):1111–1120.
   PubMed Web of Science ®Google Scholar
• Short NA, Allan NP, Schmidt NB. Sleep disturbance as a predictor of affective functioning and symptom severity among individuals with PTSD: an ecological momentary assessment study. Behav Res Ther. 2017;97:146–153.
   PubMed Web of Science ®Google Scholar
• Macera CA, Aralis HJ, Rauh MJ, et al. Do sleep problems mediate the relationship between traumatic brain injury and development of mental health symptoms after deployment? Sleep. 2013;36(1):83–90.
   PubMed Web of Science ®Google Scholar
• Wright KM, Britt TW, Bliese PD, et al. Insomnia as predictor versus outcome of PTSD and depression among Iraq combat veterans. J Clin Psychol. 2011;67(12):1240–1258.
   PubMed Web of Science ®Google Scholar
• Gehrman P, Seelig AD, Jacobson IG, et al. Predeployment sleep duration and insomnia symptoms as risk factors for new-onset mental health disorders following military deployment. Sleep. 2013;36(7):1009–1018.
   PubMed Web of Science ®Google Scholar
• Koren D, Arnon I, Lavie P, et al. Sleep complaints as early predictors of posttraumatic stress disorder: a 1-year prospective study of injured survivors of motor vehicle accidents. Am J Psychiatry. 2002;159(5):855–857.
   PubMed Web of Science ®Google Scholar
• Nappi CM, Drummond SP, Hall JM. Treating nightmares and insomnia in posttraumatic stress disorder: a review of current evidence. Neuropharmacology. 2012;62(2):576–585.
   PubMed Web of Science ®Google Scholar
• Pruiksma KE, Taylor DJ, Ruggero C, et al. A psychometric study of the fear of sleep inventory-short form (FoSI-SF). J Clin Sleep Med. 2014;10(5):551–558.
   PubMed Web of Science ®Google Scholar
• DeViva JC, Zayfert C, Mellman TA. Factors associated with insomnia among civilians seeking treatment for PTSD: an exploratory study. Behav Sleep Med. 2004;2(3):162–176.
   PubMedGoogle Scholar
• Morin CM, Vallieres A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep. 2007;30(11):1547–1554.
   PubMed Web of Science ®Google Scholar
• Schoenfeld FB, Deviva JC, Manber R. Treatment of sleep disturbances in posttraumatic stress disorder: a review. J Rehabil Res Dev. 2012;49(5):729–752.
   PubMedGoogle Scholar
• Straus LD, Drummond SP, Nappi CM, et al. Sleep variability in military-related PTSD: a comparison to primary insomnia and healthy controls. J Trauma Stress. 2015;28(1):8–16.
   PubMed Web of Science ®Google Scholar
• Mittal D, Drummond KL, Blevins D, et al. Stigma associated with PTSD: perceptions of treatment seeking combat veterans. Psychiatr Rehabil J. 2013;36(2):86–92.
   PubMed Web of Science ®Google Scholar
• Milby JB, Williams V, Hall JN, et al. Effectiveness of combined triazolam-behavioral therapy for primary insomnia. Am J Psychiatry. 1993;150(8):1259–1260.
   PubMed Web of Science ®Google Scholar
• Morin CM, Colecchi C, Stone J, et al. Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA. 1999;281(11):991–999.
   PubMed Web of Science ®Google Scholar
• Morin CM, Beaulieu-Bonneau S, Belanger L, et al. Cognitive-behavior therapy singly and combined with medication for persistent insomnia: impact on psychological and daytime functioning. Behav Res Ther. 2016;87:109–116.
   PubMed Web of Science ®Google Scholar
• Morin CM, Beaulieu-Bonneau S, Ivers H, et al. Speed and trajectory of changes of insomnia symptoms during acute treatment with cognitive-behavioral therapy, singly and combined with medication. Sleep Med. 2014;15(6):701–707.
   PubMed Web of Science ®Google Scholar
• Wiering B, de Boer D, Krol M, et al. Entertaining accurate treatment expectations while suffering from chronic pain: an exploration of treatment expectations and the relationship with patient- provider communication. BMC Health Serv Res. 2018;18(1):706.
   PubMedGoogle Scholar
• DeViva JC, Zayfert C, Pigeon WR, et al. Treatment of residual insomnia after CBT for PTSD: case studies. J Trauma Stress. 2005;18(2):155–159.
   PubMed Web of Science ®Google Scholar
• Zayfert C, DeViva JC. Residual insomnia following cognitive behavioral therapy for PTSD. J Trauma Stress. 2004;17(1):69–73.
   PubMed Web of Science ®Google Scholar
• Mohamed S, Rosenheck RA. Pharmacotherapy of PTSD in the U.S. department of veterans affairs: diagnostic- and symptom-guided drug selection. J Clin Psychiatry. 2008;69(6):959–965.
   PubMed Web of Science ®Google Scholar
• Mellman TA, Byers PM, Augenstein JS. Pilot evaluation of hypnotic medication during acute traumatic stress response. J Trauma Stress. 1998;11(3):563–569.
   PubMed Web of Science ®Google Scholar
• Cates ME, Bishop MH, Davis LL, et al. Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother. 2004;38(9):1395–1399.
   PubMed Web of Science ®Google Scholar
• Shin HJ, Rosen CS, Greenbaum MA, et al. Longitudinal correlates of aggressive behavior in help-seeking U.S. veterans with PTSD. J Trauma Stress. 2012;25(6):649–656.
   PubMed Web of Science ®Google Scholar
• Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. Review article. Sleep Med Rev. 2000;4(1):5–20.
   PubMed Web of Science ®Google Scholar
• McCall WV, Benca RM, Rosenquist PB, et al. Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18–25.
   PubMed Web of Science ®Google Scholar
• Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry. 2007;7:42.
   PubMed Web of Science ®Google Scholar
• Hawkins EJ, Malte CA, Grossbard J, et al. Comparative safety of benzodiazepines and opioids among veterans affairs patients with posttraumatic stress disorder. J Addict Med. 2013;7(5):354–362.
   PubMed Web of Science ®Google Scholar
• van Liempt S, Vermetten E, Geuze E, et al. Pharmacotherapy for disordered sleep in post-traumatic stress disorder: a systematic review. Int Clin Psychopharmacol. 2006;21(4):193–202.
   PubMed Web of Science ®Google Scholar
• Guina J, Rossetter SR, De RB, et al. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21(4):281–303.
   PubMed Web of Science ®Google Scholar
• Bateson AN. Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal. Curr Pharm Des. 2002;8(1):5–21.
   PubMed Web of Science ®Google Scholar
• Guina J, Merrill B. Benzodiazepines I: upping the care on downers: the evidence of risks, benefits and alternatives. J Clin Med. 2018;7:2.
   Web of Science ®Google Scholar
• Lund BC, Bernardy NC, Alexander B, et al. Declining benzodiazepine use in veterans with posttraumatic stress disorder. J Clin Psychiatry. 2012;73(3):292–296.
   PubMed Web of Science ®Google Scholar
• Nutt DJ, Stahl SM. Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol. 2010;24(11):1601–1612.
   PubMed Web of Science ®Google Scholar
• Dieperink ME, Drogemuller L. Zolpidem for insomnia related to PTSD. Psychiatr Serv. 1999;50(3):421.
   PubMed Web of Science ®Google Scholar
• Pollack MH, Hoge EA, Worthington JJ, et al. Eszopiclone for the treatment of posttraumatic stress disorder and associated insomnia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(7):892–897.
   PubMed Web of Science ®Google Scholar
• Abramowitz EG, Barak Y, Ben-Avi I, et al. Hypnotherapy in the treatment of chronic combat-related PTSD patients suffering from insomnia: a randomized, zolpidem-controlled clinical trial. Int J Clin Exp Hypn. 2008;56(3):270–280.
   PubMed Web of Science ®Google Scholar
• Ma G, Tc N, Cs R. Symptom presentation and prescription of sleep medications for veterans with posttraumatic stress disorder. J Nerv Ment Dis. 2017;205(2):112–118.
   PubMed Web of Science ®Google Scholar
• Warner MD, Dorn MR, Peabody CA. Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares. Pharmacopsychiatry. 2001;34(4):128–131.
   PubMed Web of Science ®Google Scholar
• Ashford JW, Miller TW. Effects of trazodone on sleep in patients diagnosed with post-traumatic stress disorder. J Contemp Psychotherapy. 1996;1996(3):221–233.
   Google Scholar
• Hertzberg MA, Feldman ME, Beckham JC, et al. Trial of trazodone for posttraumatic stress disorder using a multiple baseline group design. J Clin Psychopharmacol. 1996;16(4):294–298.
   PubMed Web of Science ®Google Scholar
• Shin JJ, Trazodone SA. StatPearls. Treasure Island (FL): StatPearls Publishing; 2017.
   Google Scholar
• Mendelson WB. A review of the evidence for the efficacy and safety of trazodone in insomnia. J Clin Psychiatry. 2005;66(4):469–476.
   PubMed Web of Science ®Google Scholar
• de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(Suppl 4):19–25.
   PubMed Web of Science ®Google Scholar
• Gandotra K, Chen P, Jaskiw GE, et al. Effective treatment of insomnia with mirtazapine attenuates concomitant suicidal ideation. J Clin Sleep Med. 2018;14(5):901–902.
   PubMed Web of Science ®Google Scholar
• Barkin RL, Schwer WA, Barkin SJ. Recognition and management of depression in primary care: a focus on the elderly. A pharmacotherapeutic overview of the selection process among the traditional and new antidepressants. Am J Ther. 2000;7(3):205–226.
   PubMedGoogle Scholar
• Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol. 2007;151(6):737–748.
   PubMed Web of Science ®Google Scholar
• Krystal AD, Durrence HH, Scharf M, et al. Efficacy and safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and outpatient trial of elderly subjects with chronic primary insomnia. Sleep. 2010;33(11):1553–1561.
   PubMed Web of Science ®Google Scholar
• Yeung WF, Chung KF, Yung KP, et al. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev. 2015;19:75–83.
   PubMed Web of Science ®Google Scholar
• Stein DJ, Davidson J, Seedat S, et al. Paroxetine in the treatment of post-traumatic stress disorder: pooled analysis of placebo-controlled studies. Expert Opin Pharmacother. 2003;4(10):1829–1838.
   PubMed Web of Science ®Google Scholar
• Davidson JR, Rothbaum BO, van der Kolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry. 2001;58(5):485–492.
   PubMed Web of Science ®Google Scholar
• Besson A, Haddjeri N, Blier P, et al. Effects of the co-administration of mirtazapine and paroxetine on serotonergic neurotransmission in the rat brain. Eur Neuropsychopharmacol. 2000;10(3):177–188.
   PubMed Web of Science ®Google Scholar
• Schneier FR, Campeas R, Carcamo J, et al. Combined mirtazapine and ssri treatment of Ptsd: a placebo-controlled trial. Depress Anxiety. 2015;32(8):570–579.
   PubMed Web of Science ®Google Scholar
• Group MoP-TSW. VA/DoD clinical practice guidelines for management of post-traumatic stress. In: Department of veterans affairs DoD, editor. Washington, DC; 2017.
   Google Scholar
• Hermes E, Sernyak M, Rosenheck R. The use of second generation antipsychotics for post-traumatic stress disorder in a US Veterans health administration medical center. Epidemiol Psychiatr Sci. 2014;23(3):281–288.
   PubMed Web of Science ®Google Scholar
• Shamliyan TA, Kane RL, Ansari MT, et al. Development of quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011;64:637–657.
   Google Scholar
• Robert S, Hamner MB, Kose S, et al. Quetiapine improves sleep disturbances in combat veterans with PTSD: sleep data from a prospective, open-label study. J Clin Psychopharmacol. 2005;25(4):387–388.
   PubMed Web of Science ®Google Scholar
• Villarreal G, Hamner MB, Qualls C, et al. Characterizing the effects of quetiapine in military post-traumatic stress disorder. Psychopharmacol Bull. 2018;48(2):8–17.
   PubMedGoogle Scholar
• VA/DoD clinical practice guidelines for management of post-traumatic stress. Washington, DC: Department of Veterans Affairs; 2017.
   Google Scholar
• Jakovljevic M, Sagud M, Mihaljevic-Peles A. Olanzapine in the treatment-resistant, combat-related PTSD–a series of case reports. Acta Psychiatr Scand. 2003;107(5):394–396. discussion 396
   PubMed Web of Science ®Google Scholar
• Stein MB, Kline NA, Matloff JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry. 2002;159(10):1777–1779.
   PubMed Web of Science ®Google Scholar
• Butterfield MI, Becker ME, Connor KM, et al. Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol. 2001;16(4):197–203.
   PubMed Web of Science ®Google Scholar
• Rothbaum BO, Killeen TK, Davidson JR, et al. Placebo-controlled trial of risperidone augmentation for selective serotonin reuptake inhibitor-resistant civilian posttraumatic stress disorder. J Clin Psychiatry. 2008;69(4):520–525.
   PubMed Web of Science ®Google Scholar
• David D, De Faria L, Mellman TA. Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD. Depress Anxiety. 2006;23(8):489–491.
   PubMed Web of Science ®Google Scholar
• Kato K, Hirai K, Nishiyama K, et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology. 2005;48(2):301–310.
   PubMed Web of Science ®Google Scholar
• Zammit G, Erman M, Wang-Weigand S, et al. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med. 2007;3(5):495–504.
   PubMed Web of Science ®Google Scholar
• Roth T, Seiden D, Wang-Weigand S, et al. A 2-night, 3-period, crossover study of ramelteon’s efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin. 2007;23(5):1005–1014.
   PubMed Web of Science ®Google Scholar
• Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70(2):197–245.
   PubMed Web of Science ®Google Scholar
• Tsujino N, Sakurai T. Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev. 2009;61(2):162–176.
   PubMed Web of Science ®Google Scholar
• Peyron C, Tighe DK, van Den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci. 1998;18(23):9996–10015.
   PubMed Web of Science ®Google Scholar
• Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron. 2003;38(5):715–730.
   PubMed Web of Science ®Google Scholar
• Flores A, Saravia R, Maldonado R, et al. Orexins and fear: implications for the treatment of anxiety disorders. Trends Neurosci. 2015;38(9):550–559.
   PubMed Web of Science ®Google Scholar
• Sun H, Kennedy WP, Wilbraham D, et al. Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013;36(2):259–267.
   PubMed Web of Science ®Google Scholar
• Herring WJ, Snyder E, Budd K, et al. Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012;79(23):2265–2274.
   PubMed Web of Science ®Google Scholar
• Citrome L. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68(12):1429–1441.
   PubMed Web of Science ®Google Scholar
• Kishi T, Matsunaga S, Iwata N. Suvorexant for primary insomnia: a systematic review and meta-analysis of randomized placebo-controlled trials. PloS one. 2015;10(8):e0136910.
   PubMed Web of Science ®Google Scholar
• Castillo PE, Younts TJ, Chavez AE, et al. Endocannabinoid signaling and synaptic function. Neuron. 2012;76(1):70–81.
   PubMed Web of Science ®Google Scholar
• Riebe CJ, Pamplona FA, Kamprath K, et al. Fear relief-toward a new conceptual frame work and what endocannabinoids gotta do with it. Neuroscience. 2012;204:159–185.
   PubMed Web of Science ®Google Scholar
• Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418(6897):530–534.
   PubMed Web of Science ®Google Scholar
• Hsiao YT, Yi PL, Li CL, et al. Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats. Neuropharmacology. 2012;62(1):373–384.
   PubMed Web of Science ®Google Scholar
• Chagas MH, Crippa JA, Zuardi AW, et al. Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol. 2013;27(3):312–316.
   PubMed Web of Science ®Google Scholar
• Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol. 2014;34(5):559–564.
   PubMed Web of Science ®Google Scholar
• Tull MT, McDermott MJ, Gratz KL. Marijuana dependence moderates the effect of posttraumatic stress disorder on trauma cue reactivity in substance dependent patients. Drug Alcohol Depend. 2016;159:219–226.
   PubMed Web of Science ®Google Scholar
• Bitencourt RM, Takahashi RN. Cannabidiol as a therapeutic alternative for post-traumatic stress disorder: from bench research to confirmation in human trials. Front Neurosci. 2018;12:502.
   PubMed Web of Science ®Google Scholar
• Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev. 2014;18(6):477–487.
   PubMed Web of Science ®Google Scholar
• Pf W, Rf W, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456–2473.
   PubMed Web of Science ®Google Scholar
• Fraser GA. The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD). CNS Neurosci Ther. 2009;15(1):84–88.
   PubMed Web of Science ®Google Scholar
• Durand D, Delgado LL, de la Parra-Pellot DM, et al. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use: A case report. Clin Schizophr Relat Psychoses. 2015;8(4):205–208.
   PubMedGoogle Scholar
• Carley DW, Paviovic S, Janelidze M, et al. Functional role for cannabinoids in respiratory stability during sleep. Sleep. 2002;25(4):391–398.
   PubMed Web of Science ®Google Scholar
• Bick BL, Szostek JH, Mangan TF. Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc. 2014;89(8):1168–1169.
   PubMed Web of Science ®Google Scholar
• Sweeney B, Talebi S, Toro D, et al. Hyperthermia and severe rhabdomyolysis from synthetic cannabinoids. Am J Emerg Med. 2016;34(1):121 e121–122.
   Web of Science ®Google Scholar
• Singh A, Saluja S, Kumar A, et al. Cardiovascular complications of marijuana and related substances: a review. Cardiol Ther. 2018;7(1):45–59.
   PubMed Web of Science ®Google Scholar
• Bonnet U, Preuss UW. The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil. 2017;8:9–37.
   PubMed Web of Science ®Google Scholar
• Macfarlane V, Christie G. Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev. 2015;34(2):147–153.
   PubMed Web of Science ®Google Scholar
• Zimmermann US, Winkelmann PR, Pilhatsch M, et al. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Dtsch Arztebl Int. 2009;106(27):464–467.
   PubMed Web of Science ®Google Scholar
• Vandrey R, Smith MT, McCann UD, et al. Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. Drug Alcohol Depend. 2011;117(1):38–44.
   PubMed Web of Science ®Google Scholar
• Smith MT, Perlis ML, Park A, et al. Comparative meta-analysis of pharmacotherapy and behavior therapy for persistent insomnia. Am J Psychiatry. 2002;159(1):5–11.
   PubMed Web of Science ®Google Scholar
• Mitchell MD, Gehrman P, Perlis M, et al. Comparative effectiveness of cognitive behavioral therapy for insomnia: a systematic review. BMC Fam Pract. 2012;13:40.
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Kanter ED, et al. Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry. 2003;160(2):371–373.
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Hoff DJ, et al. A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry. 2007;61(8):928–934.
   PubMed Web of Science ®Google Scholar
• Taylor FB, Martin P, Thompson C, et al. Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study. Biol Psychiatry. 2008;63(6):629–632.
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peterson K, Williams T, et al. A trial of prazosin for combat trauma PTSD with nightmares in active-duty soldiers returned from Iraq and Afghanistan. Am J Psychiatry. 2013;170(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Chow B, et al. Trial of prazosin for post-traumatic stress disorder in military veterans. N Engl J Med. 2018;378(6):507–517.
   PubMed Web of Science ®Google Scholar
• Kripke DF, Langer RD. Evidence for harm, comment on ‘Use of benzodiazepines or benzodiazepine related drugs and the risk of cancer: a population-based case-control study’. Br J Clin Pharmacol. 2014;78(1):186–187.
   PubMed Web of Science ®Google Scholar